Anzeige
Mehr »
Mittwoch, 06.08.2025 - Börsentäglich über 12.000 News
Warum Guardian Metal die Pentagon-gestützte Antwort auf Chinas Dominanz ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4021A | ISIN: US59102M1045 | Ticker-Symbol:
NASDAQ
05.08.25 | 21:42
2,255 US-Dollar
-1,10 % -0,025
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
METAGENOMI INC Chart 1 Jahr
5-Tage-Chart
METAGENOMI INC 5-Tage-Chart

Aktuelle News zur METAGENOMI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.Demystifying Metagenomi: Insights From 4 Analyst Reviews15
14.05.Metagenomi GAAP EPS of -$0.68, revenue of $4.12M4
14.05.Metagenomi, Inc.: Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 20251
13.05.Metagenomi, Inc. - 10-Q, Quarterly Report3
13.05.Metagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial Results154- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile...
► Artikel lesen
13.05.Metagenomi, Inc. - 8-K, Current Report1
02.05.Metagenomi, Inc.: Metagenomi to Present at Upcoming Scientific Meetings1
03.04.Metagenomi stock target cut to $7 at H.C. Wainwright23
METAGENOMI Aktie jetzt für 0€ handeln
17.03.Metagenomi files for $250M mixed securities shelf2
17.03.Metagenomi GAAP EPS of -$2.36 beats by $0.08, revenue of $52.29M beats by $0.59M3
17.03.Metagenomi, Inc. Full Year Sales Increase5
17.03.Metagenomi, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
17.03.Metagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2024 Financial Results419Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months ...
► Artikel lesen
17.03.Metagenomi, Inc. - 8-K, Current Report1
17.03.Metagenomi, Inc. - 10-K, Annual Report1
13.03.Metagenomi erzielt Durchbruch bei Genintegration22
13.03.Metagenomi, Inc.: Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems1
16.01.Metagenomi, Inc.: Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones249MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing...
► Artikel lesen
24.10.24Metagenomi, Inc.: Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT374Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly...
► Artikel lesen
03.09.24Metagenomi, Inc.: Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months135Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1